REGENXBIO Inc. provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) is active.

Johnson & Johnson enrolled about 45,000 participants for the first late-stage trial of the company’s Covid-19 single-dose vaccine candidate, with interim data expected by late January.

Regeneron Pharmaceuticals Inc. paused patient enrollment in two clinical studies testing the company’s experimental lymphoma drug, after the U.S. health regulator requested changes in trial protocols.

Moderna Inc. completed the enrollment of 30,000 participants in a late-stage study testing the company’s experimental coronavirus vaccine, with over a third of the participants from communities of color.

Enrollment in the 30,000-volunteer U.S. trial testing a Covid-19 vaccine from Pfizer and German partner BioNTech is more than 50 percent complete, according to a top Pfizer vaccine research and development scientist.

Companies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies Published: July 6, 2020 By Mark Terry BioSpace   As of June 29, there were 13 vaccines against COVID-19 in human clinical trials. According to the World Health Organization, as of June 22, there were more than 140 vaccines in development. The furthest ahead are […]

Maryland-based Novavax enrolled and dosed the company’s first patients in a Phase I/II study for a COVID-19 vaccine candidate.

A trial in China testing Gilead Sciences Inc.’s antiviral drug remdesivir in those with mild symptoms of COVID-19 was suspended due to a lack of eligible patients, according to a website maintained by the U.S. government.

A quantitative survey conducted by Continuum Clinical shows clinical research study sites are rapidly becoming more concerned about COVID-19-related interruptions to clinical trial recruitment and retention, with U.S. site concern jumping from 25 percent to 47 percent – an 88 percent increase over just 4 days.

Rafael Pharmaceuticals Inc. reached an enrollment milestone of more than 250 patients in the company’s pivotal Phase 3 clinical trial for metastatic pancreatic cancer (AVENGER 500), which is evaluating the efficacy and safety of Rafael’s lead compound CPI-613 (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy.